Please use this identifier to cite or link to this item:
|Title:||Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.|
Rodewald, Lance E.
Chang, Joo H.
Hallett, Timothy B.
|Publisher:||Oxford University Press|
|Abstract:||BACKGROUND content: In 2016, the first global viral hepatitis elimination targets were endorsed. An estimated one-third of the world's population of individuals with chronic hepatitis B virus (HBV) infection live in China and liver cancer is the sixth leading cause of mortality, but coverage of first-line antiviral treatment was low. In 2015, China was one of the first countries to initiate a consultative process for a renewed approach to viral hepatitis. We present the investment case for the scale-up of a comprehensive package of HBV interventions. METHODS content: A dynamic simulation model of HBV was developed and used to simulate the Chinese HBV epidemic. We evaluated the impact, costs, and return on investment of a comprehensive package of prevention and treatment interventions from a societal perspective, incorporating costs of management of end-stage liver disease and lost productivity costs. RESULTS content: Despite the successes of historical vaccination scale-up since 1992, there will be a projected 60 million people still living with HBV in 2030 and 10 million HBV-related deaths, including 5.7 million HBV-related cancer deaths between 2015 and 2030. This could be reduced by 2.1 million by highly active case-finding and optimal antiviral treatment regimens. The package of interventions is likely to have a positive return on investment to society of US$1.57 per US dollar invested. CONCLUSIONS content: Increases in HBV-related deaths for the next few decades pose a major public health threat in China. Active case-finding and access to optimal antiviral treatment are required to mitigate this risk. This investment case approach provides a real-world example of how applied modeling can support national dialog and inform policy planning.|
|Note:||Reproducció del document publicat a: http://dx.doi.org/10.1093/cid/ciaa134|
|It is part of:||Clinical Infectious Diseases , 2020 , vol. , num. , p. 0|
|Appears in Collections:||Articles publicats en revistes (ISGlobal)|
Files in This Item:
|Nayagam_S_Clin_Infect_Dis_2020.pdf||345.54 kB||Adobe PDF||View/Open|
This item is licensed under a Creative Commons License